Big news today: Vijoice (Alpelisib) has been approved for use by the EMA. This medication addresses an unmet medical need for patients with severe or life-threatening PIK3CA-related overgrowth spectrum (PROS) disorders ema.europa.eu/en/news/first-…

First Drug for Severe Overgrowth Disorders Approved in Europe! The European Medicines Agency has conditionally authorized the use of Vijoice (aka alpelisib/Novartis) for the treatment of patients with PROS disorders. PROS = PIK3CA-related overgrowth spectrum. A diverse group of rare genetic conditions that are characterized by uncontrolled growth of some tissues. They are caused by a mutation in the PIK3CA gene. Vijoice is indicated for patients over two years of age with severe or life-threatening manifestations of PROS, requiring systemic therapy. Vijoice showed a 20% tumor reduction in about 37.5% of patients. This is a condition that has many unmet medical needs, and this is the first step in the right direction. #PROS #GrowthDisorder #EMA #EuropeanMedicine

Following US FDA approval in April 2022, our group has reached another major milestone today with the EMA conditional approval of alpelisib for patients with severe and life-threatening PIK3CA-related overgrowth spectrum (PROS). Great news for EU patients ema.europa.eu/en/news/first-…

Our latest paper just released. Congratulations to Ilaria, Charles and the entire team 🍾🥳🔥Oncogenic PIK3CA mutations shape an immunoregulatory microenvironment in mosaic overgrowth disorders academic.oup.com/pnasnexus/a…

What extraordinary news — I’m extremely proud and honored. Thank you @eshgsociety for this very prestigious award, which I share with the entire team. 🎉🍾🥂

Bravo @casanova_lab So well deserved 🍾

Merci

Aujourd’hui nous célébrions les 10 ans d’introduction de l’alpelisib (BYL719) chez Emmanuel, le premier patient PIK3CA traité dans le monde. Immense fierté🇫🇷 10 years on alpelisib for Emmanuel, the first ever PROS patient treated. Fantastic accomplishment for all of us 🎉🥳🍾🥂

Our latest article just released. Congratulations to @IlariaGalasso and @morin_gbrl 🍾🍾🎉🎊Vascular malformations: from genetics to therapeutics | EMBO Molecular Medicine embopress.org/doi/full/10.10…

Our latest review on kidney drug repositioning in @Kidney_Int. Congrats to the 2 outstanding contributors @morin_gbrl and @IsnardPierre1👏🍾🥂Drug repurposing in PIK3CA-related overgrowth spectrum: breakthroughs from overgrowth syndromes to kidney disease kidney-international.org/art…

Wonderful team🙏🍾❤️

#France2030 | Félicitations à Guillaume Canaud @CanaudLab, lauréat d’une Chaire d’excellence en Biologie/Santé pour son projet sur les malformations vasculaires liées à KRAS. 🎯Objectif : développer des thérapies ciblées pour une médecine ultra personnalisée. 👏🏼

Excellente nouvelle et merci pour votre soutien! Ce financement devrait accélérer l’identification de nouveaux traitements pour les malformations vasculaires secondaires a des mutations de KRAS 🍾🎊🥳 Wonderful news! This is a great funding for KRAS-vascular malformations! 🙏🙏

Here is our latest publication. Somatic PIK3R1 mutations in patients and treatment with alpelisib. Congratulations to the whole team and particularly to two very talented students @morin_gbrl and @Alexandre Garneau🥳🥂🍾 EMBO Molecular Medicine embopress.org/doi/full/10.10…

Key messages: 1-No fertility issues in 3 PROS patients with prolonged exposure to alpelisib 2-No embryotoxicity 3-Unfortunately, we observed disease recurrence following alpelisib withdrawal 4-But, no resistance to drug when alpelisib was reintroduced after pregnancies.

Happy to share our latest article: « First report of successful pregnancies after treatment with alpelisib for PIK3CA-related overgrowth spectrum » Congratulations to the whole team and particularly to @morin_gbrl 🥳🍾🎉 @ejhg_journal rdcu.be/epJZ1 Key messages 👇

Our latest paper is out today in @PNAS. Congratulations to Quitterie, Sophia, Marina, and the entire team!🍾🤩🥳PIK3CA gain-of-function mutation in Schwann cells leads to severe neuropathy and aerobic glycolysis through a non-cell autonomous effect | PNAS pnas.org/doi/10.1073/pnas.24…

[PUBLICATION] First report of successful pregnancies after treatment with alpelisib for PIK3CA-related overgrowth spectrum. ➡️Fertility preserved ➡️No embryotoxicity ➡️Disease remained responsive after treatment pause 📖Details here: nature.com/articles/s41431-0…